JP2013532644A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532644A5 JP2013532644A5 JP2013520107A JP2013520107A JP2013532644A5 JP 2013532644 A5 JP2013532644 A5 JP 2013532644A5 JP 2013520107 A JP2013520107 A JP 2013520107A JP 2013520107 A JP2013520107 A JP 2013520107A JP 2013532644 A5 JP2013532644 A5 JP 2013532644A5
- Authority
- JP
- Japan
- Prior art keywords
- point
- attachment
- formula
- ethoxy
- fgf21
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 16
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 16
- -1 4-{[2- (2- {2- [2- (2- {2-[(S) -4-carboxy-4- (17-carboxyheptadecanoylamino) butyrylamino] ethoxy} ethoxy ) Acetylamino] ethoxy} ethoxy) acetylamino] methyl} benzyl Chemical group 0.000 claims 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 4
- 102220539207 28S ribosomal protein S2, mitochondrial_D102T_mutation Human genes 0.000 claims 3
- 102220478163 Ectonucleotide pyrophosphatase/phosphodiesterase family member 7_N121Q_mutation Human genes 0.000 claims 3
- 102220047964 rs587783194 Human genes 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 102220473068 Chemerin-like receptor 2_R17Q_mutation Human genes 0.000 claims 2
- 102220472274 Eukaryotic translation initiation factor 4E transporter_R36A_mutation Human genes 0.000 claims 2
- 102220487183 Growth/differentiation factor 9_K56R_mutation Human genes 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102220006124 rs1042714 Human genes 0.000 claims 2
- 102220039280 rs149338401 Human genes 0.000 claims 2
- 102200133049 rs199473351 Human genes 0.000 claims 2
- 102220229503 rs778324179 Human genes 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000004020 conductor Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 102220041198 rs201244749 Human genes 0.000 claims 1
- 102220139213 rs764056697 Human genes 0.000 claims 1
- 0 *C(C1CCNCC1)=O Chemical compound *C(C1CCNCC1)=O 0.000 description 13
- SYQVPRXWOACRGU-UHFFFAOYSA-N CC(C)(CC(C)(C)C(C)=O)C(CC(C)(C)C(O)=O)NNC Chemical compound CC(C)(CC(C)(C)C(C)=O)C(CC(C)(C)C(O)=O)NNC SYQVPRXWOACRGU-UHFFFAOYSA-N 0.000 description 2
- SZZFBZAYBYQAND-UHFFFAOYSA-N CC(C)(CC(C)(C)Cc1nnn[nH]1)CC(N)=O Chemical compound CC(C)(CC(C)(C)Cc1nnn[nH]1)CC(N)=O SZZFBZAYBYQAND-UHFFFAOYSA-N 0.000 description 1
- CUXJSAHHJLDZLD-UHFFFAOYSA-N CC(C1CCC(CN)CC1)=O Chemical compound CC(C1CCC(CN)CC1)=O CUXJSAHHJLDZLD-UHFFFAOYSA-N 0.000 description 1
- XEIRIKFEIYGNSV-UHFFFAOYSA-N CCC(C)(C)CC(C)(C)CC(N)=O Chemical compound CCC(C)(C)CC(C)(C)CC(N)=O XEIRIKFEIYGNSV-UHFFFAOYSA-N 0.000 description 1
- QVEFRIIGOBVTST-UHFFFAOYSA-N CCCC(NN=N)=N Chemical compound CCCC(NN=N)=N QVEFRIIGOBVTST-UHFFFAOYSA-N 0.000 description 1
- YNEWYSQOZRZDMA-UHFFFAOYSA-N CCc1ccc(CNC(COCCOCCNC(COCCOCCNC(CCC(C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)cc1 Chemical compound CCc1ccc(CNC(COCCOCCNC(COCCOCCNC(CCC(C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)cc1 YNEWYSQOZRZDMA-UHFFFAOYSA-N 0.000 description 1
- YQZASNIUSKXHON-UHFFFAOYSA-N NC(C(CC1)CCC1NN)=O Chemical compound NC(C(CC1)CCC1NN)=O YQZASNIUSKXHON-UHFFFAOYSA-N 0.000 description 1
- RXJUPDKQHLXTSI-UHFFFAOYSA-N NC(CC(CC1)CCC1NN)=O Chemical compound NC(CC(CC1)CCC1NN)=O RXJUPDKQHLXTSI-UHFFFAOYSA-N 0.000 description 1
- RSILLSRLAWUTAY-UHFFFAOYSA-N NCC(CC1)CCC1C(N)=O Chemical compound NCC(CC1)CCC1C(N)=O RSILLSRLAWUTAY-UHFFFAOYSA-N 0.000 description 1
- IKANTXAXGPFZJV-DHUJRADRSA-N OC(CCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCc1ccc(CI)cc1)=O)=O)=O)C(O)=O)=O)=O Chemical compound OC(CCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCc1ccc(CI)cc1)=O)=O)=O)C(O)=O)=O)=O IKANTXAXGPFZJV-DHUJRADRSA-N 0.000 description 1
- OITFIMMAIDBVET-QNGWXLTQSA-N OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCc1ccc(CI)cc1)=O)=O)=O)C(O)=O)=O)=O Chemical compound OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCc1ccc(CI)cc1)=O)=O)=O)C(O)=O)=O)=O OITFIMMAIDBVET-QNGWXLTQSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010001087 | 2010-07-20 | ||
| CNPCT/CN2010/001087 | 2010-07-20 | ||
| US37407210P | 2010-08-16 | 2010-08-16 | |
| US61/374,072 | 2010-08-16 | ||
| PCT/EP2011/062238 WO2012010553A1 (en) | 2010-07-20 | 2011-07-18 | N-terminal modified fgf21 compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532644A JP2013532644A (ja) | 2013-08-19 |
| JP2013532644A5 true JP2013532644A5 (enExample) | 2014-08-07 |
| JP6069198B2 JP6069198B2 (ja) | 2017-02-01 |
Family
ID=44454019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520107A Expired - Fee Related JP6069198B2 (ja) | 2010-07-20 | 2011-07-18 | Ｎ末端が修飾されたｆｇｆ２１化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9655974B2 (enExample) |
| EP (1) | EP2595647A1 (enExample) |
| JP (1) | JP6069198B2 (enExample) |
| CN (1) | CN103415300B (enExample) |
| WO (1) | WO2012010553A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2796459C (en) | 2010-04-16 | 2016-05-24 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using fgf-1 |
| CN103596584B (zh) * | 2011-06-15 | 2016-12-14 | 诺沃—诺迪斯克有限公司 | 多取代的胰岛素 |
| PL2726511T3 (pl) | 2011-07-01 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| SG11201504815QA (en) | 2012-12-27 | 2015-07-30 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2015061331A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
| CA2928135A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (fgf) 1 and methods of use |
| NZ718962A (en) | 2013-10-28 | 2019-12-20 | Ngm Biopharmaceuticals Inc | Cancer models and associated methods |
| TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
| AU2015209131B2 (en) | 2014-01-24 | 2020-06-25 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| WO2015138278A1 (en) | 2014-03-11 | 2015-09-17 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| EP3155005A4 (en) | 2014-06-16 | 2018-07-11 | NGM Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| CN114129709A (zh) | 2014-10-23 | 2022-03-04 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| HUE044783T2 (hu) | 2014-12-23 | 2019-11-28 | Novo Nordisk As | FGF21 származékok és alkalmazásaik |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| AR106133A1 (es) * | 2015-09-24 | 2017-12-13 | Genentech Inc | Métodos para el tratamiento de la epilepsia |
| KR102670157B1 (ko) | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| KR102668200B1 (ko) | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| AU2016344134A1 (en) | 2015-10-30 | 2018-05-31 | Salk Institute For Biological Studies | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs |
| CA3003616C (en) | 2015-11-09 | 2020-07-28 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| WO2017220706A1 (en) | 2016-06-22 | 2017-12-28 | Novo Nordisk A/S | Pharmaceutical compositions of fgf21 derivatives and uses thereof |
| US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
| CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技（上海）有限公司 | 双特异性抗体及其制备方法与用途 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CA3034399A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN110121355B (zh) | 2016-11-10 | 2023-09-12 | 株式会社柳韩洋行 | 用于预防或治疗肝炎、肝纤维化和肝硬化的包含融合蛋白的药物组合物 |
| CN108619490A (zh) | 2017-03-22 | 2018-10-09 | 天士力医药集团股份有限公司 | 一种长效化突变的人源成纤维生长因子的新用途 |
| AU2018256256B2 (en) | 2017-04-21 | 2023-02-23 | Yuhan Corporation | Method for producing dual function proteins and its derivatives |
| IL275499B2 (en) | 2017-12-22 | 2024-03-01 | Novartis Ag | Methods of treating metabolic disorders with fgf21 variants |
| US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
| CN115322794B (zh) | 2020-01-11 | 2025-09-19 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| KR20220021207A (ko) | 2020-08-13 | 2022-02-22 | 주식회사 나이벡 | 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물 |
| CA3224743A1 (en) | 2021-07-14 | 2023-01-19 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion polypeptides for metabolic disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001032678A1 (en) | 1999-11-05 | 2001-05-10 | Smithkline Beecham Corporation | sbgFGF-19a |
| US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
| EP1329227A1 (en) | 2002-01-22 | 2003-07-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells |
| EA008831B1 (ru) | 2003-06-12 | 2007-08-31 | Эли Лилли Энд Компани | Слитые белки аналогов glp-1 |
| JP2007537981A (ja) * | 2003-09-19 | 2007-12-27 | ノボ ノルディスク アクティーゼルスカブ | 新規の血漿タンパク質親和性タグ |
| CA2539253A1 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| AU2004303783A1 (en) * | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| JP2007531715A (ja) | 2004-03-17 | 2007-11-08 | イーライ リリー アンド カンパニー | グリコール結合ｆｇｆ−２１化合物 |
| DK1751184T3 (da) | 2004-05-13 | 2009-11-23 | Lilly Co Eli | FGF-21 fusionsproteiner |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| ES2542228T3 (es) | 2004-07-08 | 2015-08-03 | Novo Nordisk A/S | Marcas de prolongación polipeptídica que comprenden un resto de tetrazol |
| MX2007002616A (es) | 2004-09-02 | 2007-05-16 | Lilly Co Eli | Muteinas de factor de crecimiento de fibroblasto 21. |
| WO2006028714A1 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| EP1814573B1 (en) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| US7655627B2 (en) | 2004-12-14 | 2010-02-02 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| PL2068909T3 (pl) | 2007-03-30 | 2012-09-28 | Ambrx Inc | Modyfikowane polipeptydy fgf-21 i ich zastosowanie |
| SI2068909T1 (sl) * | 2007-03-30 | 2012-09-28 | Ambrx Inc | Modificirani fgf-21 polipeptidi in njihova uporaba |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| EP2358749B1 (en) | 2008-10-10 | 2018-07-18 | Amgen, Inc | Fgf21 mutants and uses thereof |
| ES2692495T3 (es) * | 2009-01-23 | 2018-12-03 | Novo Nordisk A/S | Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos |
-
2011
- 2011-07-18 CN CN201180045216.4A patent/CN103415300B/zh not_active Expired - Fee Related
- 2011-07-18 US US13/809,273 patent/US9655974B2/en not_active Expired - Fee Related
- 2011-07-18 WO PCT/EP2011/062238 patent/WO2012010553A1/en not_active Ceased
- 2011-07-18 JP JP2013520107A patent/JP6069198B2/ja not_active Expired - Fee Related
- 2011-07-18 EP EP11732488.9A patent/EP2595647A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532644A5 (enExample) | ||
| RU2011134454A (ru) | Производные fgf21 со связующим альбумина а-в-с-d-e- и их применение | |
| JP2017081939A5 (enExample) | ||
| JP2016512425A5 (enExample) | ||
| JP2016052315A5 (enExample) | ||
| JP2012529463A5 (enExample) | ||
| JP2009530399A5 (enExample) | ||
| CL2013003406A1 (es) | Compuestos derivados de dolastatina unidos a aminoacidos no naturales; procedimiento de preparacion; composiciones farmaceuticas, útiles en el tratamiento del cancer de mamas. | |
| MY161664A (en) | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same | |
| NZ591130A (en) | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof | |
| RU2017125050A (ru) | Производные fgf21 и их применения | |
| EP2390265A3 (en) | Insulinotropic peptide derivative wherein its N-terminal amino acid is modified | |
| JP2015518831A5 (enExample) | ||
| JP2011006428A5 (enExample) | ||
| JP2011173914A5 (enExample) | ||
| JP2009530398A5 (enExample) | ||
| RU2014111472A (ru) | Способ ингибирования клеточной активации, вызываемой инсулиноподобным фактором роста 1 | |
| MY162564A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| JP2009292810A5 (enExample) | ||
| JP2011511933A5 (enExample) | ||
| HRP20220455T1 (hr) | Modificirane aminokiseline koje sadrže azid grupu | |
| JP2010523476A5 (enExample) | ||
| JP2017507181A5 (enExample) | ||
| EP2457918A3 (en) | Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes | |
| JP2016534059A5 (enExample) |